Skip to main content
ARGXargenx SEBuy Wait6.9·$1032.86
ARGX · Why this verdict

Why argenx (ARGX) is rated BUY WAIT

Updated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

VerdictBUY WAIT
Overall score6.9/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis

Engine thesis — one sentence

This healthcare franchise combines a perfect four-quarter earnings beat streak averaging 23.2% positive surprise, 63% revenue growth, a maximum Piotroski financial health score, and a golden-cross technical breakout — one of the highest-quality growth setups in the universe — though the 5.1% upside at the current spot price creates an asymmetry gap that favors waiting for a pullback near the $812.92 entry target.

Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.

Thesis pillars

Business quality scores 9.0 out of 10, supported by a maximum (9 out of 9) Piotroski financial health score, 31% gross margins, and strong operating and net margins — the hallmarks of a financially healthy franchise.

Stable
Quality
Expectation
Gross margin remains above 28% and the Piotroski score stays at 8 or above for the next two annual reports.

CounterA forward P/E of 24.0x and PEG of 1.48 price in strong near-term growth continuation; if margin expansion stalls, the premium multiple could compress, negating much of the quality benefit for holders who pay today's price.

The company has beaten consensus earnings estimates in all four reported quarters with an average positive surprise of 23.2%, demonstrating a sustained pattern of under-promising and over-delivering that tends to support premium multiples.

Improving
Catalyst
Expectation
Earnings beats continue for the next two quarterly reports with an average positive surprise above 10%.

CounterDespite the perfect beat record, OBV has been falling — signaling institutional distribution on price strength — and implied volatility at 67% means the options market is pricing in an outsized move at the next earnings print, which cuts both ways.

Revenue grew 63% year-over-year, the highest growth rank in the scorecard, positioning the company to sustain or grow into a premium multiple if the expansion trajectory continues for several more quarters.

Stable
Growth
Expectation
Revenue growth sustains above 30% year-over-year for the next two consecutive quarters.

CounterGrowth at this pace naturally invites competitive responses, and falling OBV suggests the market may already be de-rating the stock on expectations of natural deceleration — a pattern where the fastest-growing periods can also mark the peak of valuation expansion.

A golden cross has formed with the stock above all major moving averages, RSI at 66, and MACD in a bullish configuration — a technically strong setup associated with continuation moves in quality growth names.

Improving
Momentum
Expectation
The stock holds above the 200-day moving average for two consecutive months and MACD remains in a positive crossover configuration.

CounterDespite the golden cross, volume is distributing rather than accumulating (falling OBV), which can precede a failed breakout; implied volatility at 67% means the next catalyst event carries substantial two-directional risk.

At the current price, only 5.1% of upside remains to the near-term resistance target of $928.90; the suggested entry near $812.92 would restore a more favorable risk/reward of roughly 1.6-to-1 and represents a disciplined starting point for an initial position.

TrippedStable
Engine gate (failed)
Expectation
The stock pulls back within 8% of the $812.92 entry level within the next quarter, offering improved asymmetry for a first tranche.

CounterThe golden cross is already confirmed and momentum scores above the strong threshold — the stock may not offer a meaningful pullback toward $812, meaning strict entry discipline risks missing a high-quality name that continues its breakout.

Per-dimension breakdown

Value

3.9/10data confidence 83%
ComponentSub-score
P/E3.3
P/S2.3
Fwd P/E4.9
PEG5.0
Analyst target4.0
  • Forward P/E: 25.3x
  • PEG: 1.51

Quality

8.1/10data confidence 100%
ComponentSub-score
ROE7.9
ROA7.8
Gross margin7.8
Op margin10.0
Net margin10.0
Current ratio7.9
FCF quality3.6
Moat9.0
Piotroski F8.9
  • Strong margins: 32%
  • Earnings quality RED FLAG: 44% FCF/NI
  • Wide economic moat
  • Compounder quality: strong returns + growth

Growth

10.0/10data confidence 67%
ComponentSub-score
Rev growth10.0
EPS growth10.0
  • Strong growth: 59% YoY

Momentum

7.6/10data confidence 100%
ComponentSub-score
RSI4.2
MACD10.0
OBV10.0
MA position9.0
Volume4.7
  • Overbought (RSI 75)
  • Volume accumulation (rising OBV)
  • Above 200-day MA

Sentiment

7.3/10data confidence 100%
ComponentSub-score
LLM sentiment6.6
Analyst rating9.0
Price target5.9
  • LLM news sentiment: +0.33 (n=10)

Insider

5.0/10data confidence 50%

Peer rank

7.0/10data confidence 80%
ComponentSub-score
value rank3.3
quality rank8.5
growth rank7.4
  • Superior ROE vs peers
  • Conservative debt levels

Technical

3.8/10data confidence 100%
ComponentSub-score
bollinger0.0
support resistance0.1
52w position10.0
gap5.0

Risk (lower is worse)

6.0/10data confidence 100%
ComponentSub-score
short interest8.9
days to cover6.2
volatility3.9
put call4.5
implied vol5.2
debt equity10.0
news risk3.0

Catalyst

7.6/10data confidence 100%
ComponentSub-score
erm5.0
earnings history10.0
earnings timing5.0
surprise avg10.0
news activity8.0
  • Perfect beat streak: 4Q

How the verdict was assembled

Engine trigger

Wide-moat business. Accumulate on weakness.

Engine technical detail
verdict_path: L4:PATH_E_WIDE_MOAT|ENTRY_STICKY:PRIOR_STILL_VIABLE
Passed (8)
  • MOMENTUM:7.6>=5.5
  • INSIDER:OK
  • 8K:CLEAN
  • NEWS_BOOST:ANALYST:0.70
  • NEWS_BOOST:ANALYST_CLUSTER(9)
  • EARNINGS_PROXIMITY:64d clear
  • SEMI_CYCLE_PEAK:CLEAR
  • MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
  • ASYMMETRY:-0.3=NEGATIVE
Warning (0)

none

Reward-to-Risk
-0.29
Upside
-4.3%
Downside
15.0%
Sizing output
STARTER

Setup No clear chart pattern; technical signals are mixed

EdgeNo clear edge No clear edge identified

SuitabilitySpeculative Binary industry: Biotechnology

Investment implication

The STRONG_BUY_WAIT verdict reflects the ASYMMETRY gate's -0.3=NEGATIVE outcome against Growth at 10.0 and asymmetric R:R of -0.29.

The strongest dimensions are Growth at 10.0, Quality at 8.1, and Momentum at 7.6; the weakest are Technical at 3.8, Value at 3.9, and Insider at 5.0. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of -0.29 and an engine sizing output of STARTER.

What would invalidate the thesis

Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.

  • P1Perfect Four Quarter Beat Streak

    Trip ifEPS surprise falls below 0% for any single quarter, ending the perfect beat streak.

  • P2Exceptional Business Quality

    Trip ifGross margin compresses below 25% from current 31% for 2 consecutive quarters.

  • P3Sixty Three Percent Revenue Growth

    Trip ifRevenue growth falls below 20% YoY for 2 consecutive quarters.

  • P4Golden Cross Breakout Momentum

    Trip ifStock closes below the 200-day moving average for 2 consecutive weeks.

  • P5Spot Upside Gap Favors Entry DisciplineTripped

    Trip ifStock price closes above $950.00, exceeding the $928.90 target and making the entry-discipline framework obsolete.

Engine reasoning is mechanically derived from pipeline gate outputs. See decision view.

Home Stocks ARGX Why this verdict